HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3′-azido-3′-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4 + HeLa cells. Fifty percent inhibitory dose (ID 50 ) values of 18 isolates from untreated individuals ranged between 0.01 μ M and 0.05 μ M . In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID 50 or ID 95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in ID 50 . The latter isolates were also insensitive to 3′-azido-2′,3′-dideoxyuridine; however, the isolates were still sensitive to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-2′,3′-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a clinical trial, its dramatic short-term effects in delaying the death of AIDS patients (109) led to its rapid approval for use, although the virus rebounded after a few months due to the appearance of mutations in RT that render it AZT resistant (110).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [110]
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Klecker, R. W., Collins, J. M., Yarchoan, R., Thomas, R., Jenkins, J. F., Broder, S., & Myers, C. E. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.49 · Cited by 381
Site-specific mutagenesis of AIDS virus reverse transcriptase
Larder, B. A., Purifoy, D. J. M., Powell, K. L., & Darby, G. (1987) · Nature · doi:10.1038/327716a0 · Cited by 312
Self-citationDevelopment of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
Chesebro, B., & Wehrly, K. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3779-3788.1988 · Cited by 304
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Self-citationISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY
Burns, W., Santos, G., Saral, R., Laskin, O., Lietman, P., Mclaren, C., & Barry, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91620-8 · Cited by 240
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Self-citation
Cited by
Items 301–400 of 1,000
Lethal Mutagenesis: Targeting the Mutator Phenotype in Cancer
Fox, E., & Loeb, L. A. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.005 · Cited by 86
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs)
Goldschmidt, V., & Marquet, R. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.028 · Cited by 86
More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1
Feder, A. F., Rhee, S., Holmes, S., Shafer, R. W., Petrov, D. A., & Pennings, P. S. (2016) · eLife · doi:10.7554/elife.10670 · Cited by 86
Degar, S., Prince, A. M., Pascual, D., Lavie, G., Levin, B., Mazur, Y., Lavie, D., Ehrlich, L. S., Carter, C., & Meruelo, D. (1992) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1992.8.1929 · Cited by 86
Kavlick, M. F., Shirasaka, T., Kojima, E., Pluda, J. M., Hui, F. K., Yarchoan, R., & Mitsuya, H. (1995) · Antiviral Research · doi:10.1016/0166-3542(95)00044-m · Cited by 86
Gupta, S., & Gollapudi, S. V. S. (1993) · Journal of Clinical Immunology · doi:10.1007/bf00920237 · Cited by 84
Kedar, P. S., Abbotts, J., Kovács, T., Lesiak, K. B., Torrence, P. F., & Wilson, S. H. (1990) · Biochemistry · doi:10.1021/bi00467a003 · Cited by 84
Lamarre, D., Croteau, G., Wardrop, E., Bourgon, L., Thibeault, D., Clouette, C., Vaillancourt, M., Cohen, É. A., Pargellis, C., Yoakim, C., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.965 · Cited by 83
Imamichi, T., Berg, S. C., Imamichi, H., Lopez, J. C., Metcalf, J. A., Falloon, J., & Lane, H. C. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.10958-10964.2000 · Cited by 83
Synthesis of New Covalently Bound κ-Carrageenan−AZT Conjugates with Improved Anti-HIV Activities
Vlieghe, P., Clerc, T., Pannecouque, C. C., Witvrouw, M., Clercq, E. D., Salles, J., & Kraus, J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010969d · Cited by 83
Human immunodeficiency virus protease: A target for aids therapy
Debouck, C. M., & Metcalf, B. W. (1990) · Drug Development Research · doi:10.1002/ddr.430210102 · Cited by 83
Buckheit, R. W., Roberson, J. L., Lackman-Smith, C., Wyatt, J. R., Vickers, T. A., & Ecker, D. J. (1994) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1994.10.1497 · Cited by 82
Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, D4T)
Riddler, S. A., Anderson, R. E., & Mellors, J. W. (1995) · Antiviral Research · doi:10.1016/0166-3542(95)00016-f · Cited by 82
Gu, Z., Salomón, H., Cherrington, J. M., Mulato, A. S., Chen, M.-S., Yarchoan, R., Foli, A., Sogocio, K. M., & Wainberg, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1888 · Cited by 82
Hayashi, S., Norbeck, D. W., ROSENBROOK, W. J., Fine, R. L., Matsukura, M., PLATTNER, J. J., Broder, S., & Mitsuya, H. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.287 · Cited by 82
Targets and strategies for the antiviral chemotherapy of AIDS
Clercq, E. D. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90115-o · Cited by 82
Antiherpetic activities of various protein bound polysaccharides isolated from Ganoderma lucidum
Eo, S. K., Kim, Y.-S., Lee, C., & Han, S.-S. (1999) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(99)00086-0 · Cited by 81
3 The Medicinal Chemistry of the Azido Group
Griffin, R. J. (1994) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70020-1 · Cited by 81
Perno, C. F., Cooney, D., Gao, W., Hao, Z., Johns, D., Foli, A., Hartman, N., Caliò, R., Broder, S., & Yarchoan, R. (1992) · Blood · doi:10.1182/blood.v80.4.995.995 · Cited by 81
Condra, J. H., Emini, E. A., Gotlib, L., Graham, D. J., Schlabach, A. J., Wolfgang, J., Colonno, R. J., & Sardana, V. V. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.7.1441 · Cited by 81
Economic and Policy Implications of Early Intervention in HIV Disease
Arno, P. S., Shenson, D., Siegel, N. F., Franks, P., & Lee, P. R. (1989) · JAMA · doi:10.1001/jama.1989.03430110083033 · Cited by 81
Genetic Draft and Quasi-Neutrality in Large Facultatively Sexual Populations
Neher, R. A., & Shraiman, B. I. (2011) · Genetics · doi:10.1534/genetics.111.128876 · Cited by 80
Rice, W. G., Schaeffer, C. A., Graham, L. M., Bu, M., McDougal, J. S., Orloff, S. L., Villinger, F. J., Young, M. R., Oroszlan, S. I., & Fesen, M. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9721 · Cited by 80
Liebes, L., Mazur, Y., Freeman, D., Lavie, D., Lavie, G., Kudler, N., Mendoza, S., Levin, B., Hochster, H., & Meruelo, D. (1991) · Analytical Biochemistry · doi:10.1016/0003-2697(91)90298-8 · Cited by 81
Understanding drug resistance for monotherapy treatment of HIV infection
Kirschner, D. E., & Webb, G. F. (1997) · Bulletin of Mathematical Biology · doi:10.1007/bf02458429 · Cited by 80
Clinically Relevant Genotype Interpretation of Resistance to Didanosine
Marcelin, A., Flandre, P., Pavie, J., Schmidely, N., Wirden, M., Lada, O., Chiche, D. A., Molina, J., & Cálvez, V. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1739-1744.2005 · Cited by 80
Tachedjian, G., Mellors, J. W., BAZMI, H., Birch, C. J., & MILLS, J. S. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.7171-7181.1996 · Cited by 80
Early Treatment for HIV: The Time Has Come
FRIEDLAND, G. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004053221409 · Cited by 80
Mathematical Analysis of a Two Strain HIV/AIDS Model with Antiretroviral Treatment
Bhunu, C. P., Garira, W., & Magombedze, G. (2009) · Acta Biotheoretica · doi:10.1007/s10441-009-9080-2 · Cited by 79
Pengsuparp, T., Serit, M., Hughes, S. H., Soejarto, D. D., & Pezzuto, J. M. (1996) · Journal of Natural Products · doi:10.1021/np960399y · Cited by 79
N-Carboxymethylchitosan-N,O-sulfate as an anti-HIV-1 agent
Sosa, M. A. G., Fazely, F., Koch, J. A., Vercellotti, S. V., & Ruprecht, R. M. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91443-g · Cited by 79
A New Type of G→A Hypermutation Affecting Human Immunodeficiency Virus
Fitzgibbon, J. E., Mazar, S., & Dubin, D. T. (1993) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1993.9.833 · Cited by 79
Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate.
Mazumder, A., Cooney, D., Agbaria, R., Gupta, M., & Pommier, Y. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5771 · Cited by 67
Richman, D. D. (1992) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1992.8.1065 · Cited by 78
Self-citationZeidner, N. S., Myles, M. H., Mathiason, C. K., Dreitz, M. J., Mullins, J. I., & Hoover, E. A. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.9.1749 · Cited by 77
HIV-1 Reverse Transcriptase Resistance to Nonnucleoside Inhibitors
Spence, R., Anderson, K. S., & Johnson, K. A. (1996) · Biochemistry · doi:10.1021/bi952058+ · Cited by 77
Johnson, V. A., Barlow, M. A., Merrill, D. P., Chou, T., & Hirsch, M. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/161.6.1059 · Cited by 77
Reverse transcription of the HIV‐1 pandemic
Basavapathruni, A., & Anderson, K. S. (2007) · The FASEB Journal · doi:10.1096/fj.07-8697rev · Cited by 76
Shen, L., Rabi, S. A., Sedaghat, A. R., Shan, L., Lai, J., Xing, S., & Siliciano, R. F. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002304 · Cited by 68
Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate
Fujiwara, M., Ijichi, K., Tokuhisa, K., Katsuura, K., Shigeta, S., Konno, K., Wang, G. Y., Uemura, D., Yokota, T., & Baba, M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.1.271 · Cited by 76
Major salivary gland lymphoepithelial lesions and the acquired immunodeficiency syndrome
Terry, J. H., Loree, T. R., Thomas, M. D., & Marti, J. R. (1991) · The American Journal of Surgery · doi:10.1016/0002-9610(91)90141-y · Cited by 76
The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy
Coen, D. M. (1991) · Antiviral Research · doi:10.1016/0166-3542(91)90010-o · Cited by 76
Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959
Eberle, J., BECHOWSKY, B., Rose, D., Hauser, U., von der Helm, K., Gürtler, L. G., & Nitschko, H. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.671 · Cited by 76
Marcy, A. I., Hwang, C. B. C., Ruffner, K. L., & Coen, D. M. (1990) · Journal of Virology · doi:10.1128/jvi.64.12.5883-5890.1990 · Cited by 76
Yarchoan, R., Jm, P., Perno, C. F., Mitsuya, H., & Broder, S. (1991) · Blood · doi:10.1182/blood.v78.4.859.859 · Cited by 76
Viral Quasispecies and Fitness Variations
Domingo, E., Escarmís, C., Menéndez‐Arias, L., & Holland, J. J. (1999) · Elsevier eBooks · doi:10.1016/b978-012220360-2/50008-8 · Cited by 75
Interferon and Other Biologic Agents for the Treatment of Kaposi's Sarcoma
Krown, S. E. (1991) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30443-x · Cited by 74
Japour, A. J., Chatis, P. A., Eigenrauch, H. A., & Crumpacker, C. S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3092 · Cited by 74
Exosome-associated release, uptake, and neurotoxicity of HIV-1 Tat protein
Rahimian, P., & He, J. J. (2016) · Journal of NeuroVirology · doi:10.1007/s13365-016-0451-6 · Cited by 73
Baba, M., Okamoto, M., Makino, M., Kimura, Y., Ikeuchi, T., Sakaguchi, T., & Okamoto, T. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1250 · Cited by 73
Antiretroviral Therapy in AIDS
Broder, S. E., Mitsuya, H., Yarchoan, R., & Pavlakis, G. N. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-8-604 · Cited by 73
Prasad, V. R., Lowy, I., Santos, T. D. L., Chiang, L. W., & Goff, S. P. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11363 · Cited by 73
Kaye, S., Loveday, C., & Tedder, R. S. (1992) · Journal of Medical Virology · doi:10.1002/jmv.1890370402 · Cited by 73
HIV-I-associated central nervous system dysfunction
Krebs, F. C., Ross, H. L., McAllister, J., & Wigdahl, B. L. (2000) · Advances in pharmacology · doi:10.1016/s1054-3589(00)49031-9 · Cited by 73
Antiviral resistance: mechanisms, clinical significance, and future implications
Kimberlin, D. W., & Whitley, R. J. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/37.3.403 · Cited by 72
Dolin, R., Amato, D. A., Fischl, M. A., Pettinelli, C., Beltangady, M., Liou, S. H., Brown, M. D., Cross, A. P., Hirsch, M. S., & Hardy, W. D. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.9.961 · Cited by 72
The Discovery of Reverse Transcriptase
Coffin, J. M., & Fan, H. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-035556 · Cited by 71
Métifiot, M., Maddali, K., Naumova, A., Zhang, X., Marchand, C., & Pommier, Y. (2010) · Biochemistry · doi:10.1021/bi100130f · Cited by 68
Bennett, D., Jordan, M. R., Bertagnolio, S., Hong, S. Y., Ravasi, G., McMahon, J. H., Saadani, A., & Kelley, K. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis207 · Cited by 71
Arion, D., Sluis‐Cremer, N., & Parniak, M. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9251 · Cited by 71
Buckheit, R. W., Fliakas-Boltz, V., DECKER, W., ROBERSON, J., Stup, T. L., Pyle, C., White, E. A., McMahon, J. B., Currens, M. J., & Boyd, M. R. (1995) · Antiviral Research · doi:10.1016/0166-3542(94)00069-k · Cited by 71
Conlon, C. P., Klenerman, P., Edwards, A. M., Larder, B. A., & Phillips, R. E. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.2.411 · Cited by 71
Self-citationMorgan, R. A., & WALKER, R. E. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.10-1281 · Cited by 70
LOCARNINI, S. A., & Birch, C. J. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80118-4 · Cited by 70
Martin, J. C., Hitchcock, M. J. M., Clercq, E. D., & Prusoff, W. H. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.006 · Cited by 69
Gordon, R. K., Ginalski, K., Rudnicki, W. R., Rychlewski, L., Pankaskie, M. C., Bujnicki, J. M., & Chiang, P. K. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03726.x · Cited by 69
HIV Resistance to Nevirapine and Other Non-Nucleoside Reverse Transcriptase Inhibitors
Wainberg, M. A. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200309011-00002 · Cited by 69
Romero, D. L., Olmsted, R. A., Poel, T. J., Morge, R. A., Biles, C., Keiser, B. J., Kopta, L. A., Friis, J. M., Hosley, J. D., Stefanski, K. J., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960158n · Cited by 69
Mayers, D. L., Mikovits, J. A., Joshi, B. H., HEWLETT, I. K., Estrada, J. S., Wolfe, A. D., Garcia, G. E., Doctor, B. P., Burke, D. S., & Gordon, R. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.1.215 · Cited by 69
Loya, S., Rudi, A., Kashman, Y., & Hizi, A. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440085 · Cited by 69
Clercq, E. D. (1995) · Reviews in Medical Virology · doi:10.1002/rmv.1980050305 · Cited by 69
Gu, Z., Gao, Q., Faust, E. A., & Wainberg, M. A. (1995) · Journal of General Virology · doi:10.1099/0022-1317-76-10-2601 · Cited by 68
Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Early Events in Reverse Transcription
Arts, E. J., & Wainberg, M. A. (1996) · Advances in virus research · doi:10.1016/s0065-3527(08)60071-8 · Cited by 68
Glutamine 151 participates in the substrate dNTP binding function of HIV-1 reverse transcriptase
Sarafianos, S. G., Pandey, V. N., Kaushik, N., & Modak, M. J. (1995) · Biochemistry · doi:10.1021/bi00021a036 · Cited by 68
Hammer, S., Crumpacker, C. S., D’Aquila, R. T., Jackson, J. B., Lathey, J. L., Livnat, D., & Reichelderfer, P. S. (1993) · Journal of Clinical Microbiology · doi:10.1128/jcm.31.10.2557-2564.1993 · Cited by 68
Serotypes Responsible for Invasive Streptococcus pneumoniae Infections among Children in Connecticut
Shapiro, E. D., & AUSTRIAN, R. C. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.1.212 · Cited by 68
Scherrer, A., von Wyl, V., Yang, W.-L., Kouyos, R. D., Böni, J., Yerly, S., Klimkait, T., Aubert, V., Cavassini, M. L., Battegay, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw128 · Cited by 67
The Biology and Evolution of HIV
Hutchinson, J. F. (2001) · Annual Review of Anthropology · doi:10.1146/annurev.anthro.30.1.85 · Cited by 68
Uryu, T., Ikushima, N., Katsuraya, K., Shoji, T., Takahashi, N., Yoshida, T., Kanno, K., Murakami, T., Nakashima, H., & Yamamoto, N. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90317-c · Cited by 67
Byrnes, V. W., Emini, E. A., Schleif, W. A., Condra, J. H., Schneider, C. L., Long, W. J., Wolfgang, J., Graham, D. J., Gotlib, L., & Schlabach, A. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1404 · Cited by 67
Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction.
Bader, J. P., McMahon, J. B., Schultz, R. J., Narayanan, V. L., Pierce, J. B., Harrison, W., Weislow, O. S., Midelfort, C. F., Stinson, S. F., & Boyd, M. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6740 · Cited by 67
Gingeras, T., Prodanovich, P., Latimer, T., Guatelli, J. C., Richman, D. D., & Barringer, K. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.6.1066 · Cited by 67
Self-citationMurakami, T., Kumakura, S., Yamazaki, T., Tanaka, R., Hamatake, M., Okuma, K., Huang, W., Toma, J., Komano, J. A., Yanaka, M., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01727-08 · Cited by 66
Ueno, T., & Mitsuya, H. (1997) · Biochemistry · doi:10.1021/bi962393d · Cited by 66
Human immunodeficiency virus I-induced expression of P-glycoprotein
Gollapudi, S. V. S., & Gupta, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90783-j · Cited by 66
Zidovudine-Associated Embryonic Toxicity in Mice
Toltzis, P., Marx, C. M., Kleinman, N. R., Levine, E. M., & Schmidt, E. V. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.6.1212 · Cited by 66
Carroll, S. S., Geib, J., Olsen, D. B., Stahlhut, M. W., Shafer, J. A., & Kuo, L. C. (1994) · Biochemistry · doi:10.1021/bi00174a018 · Cited by 66
Eron, J. J., Johnson, V. A., Merrill, D. P., Chou, T., & Hirsch, M. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.7.1559 · Cited by 66
The relentless rise of resistance?
Wise, R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh340 · Cited by 65
Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system
Sawchuk, R. J., & Yang, Z. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00017-4 · Cited by 65
Complications of RNA Heterogeneity for the Engineering of Virus Vaccines and Antiviral Agents
Domingo, E., & Holland, J. J. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3424-2_2 · Cited by 64
Daluge, S. M., Purifoy, D. J. M., Savina, P. M., Clair, M. H. S., Parry, N. R., Dev, I. K., Novak, P., AYERS, K. M., Reardon, J. E., & Roberts, G. B. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1590 · Cited by 64
Albert, J., Wahlberg, J., Lundeberg, J., Cox, S., Sandström, E., Wahrén, B., & Uhlén, M. (1992) · Journal of Virology · doi:10.1128/jvi.66.9.5627-5630.1992 · Cited by 64
Wilde, M. I., & Langtry, H. D. (1993) · Drugs · doi:10.1007/bf03259112 · Cited by 64
Stilianakis, N. I., Boucher, C. A., de Jong, M. D., van Leeuwen, R., Schuurman, R., & de Boer, R. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.1.161-168.1997 · Cited by 63
Dueweke, T. J., Kézdy, F. J., Waszak, G. A., Deibel, M. R., & Tarpley, W. G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48451-7 · Cited by 63
Nucleoside Reverse Transcriptase Inhibitor Resistance
Loveday, C. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200103011-00003 · Cited by 63
Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs
Mayers, D. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00067-3 · Cited by 63
2′,3′-Didehydro-2′,3′-dideoxythymidine (D4T), an anti-HIV Agent
Hitchcock, M. J. M. (1991) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029100200301 · Cited by 63
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group
Mayers, D., Japour, A. J., Arduino, J. M., Sm, H., Reichman, R. C., Wagner, K., Chung, R. C. Y., Lane, J. R., Crumpacker, C. S., & McLeod, G. X. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.307 · Cited by 63
Metadata
- Authors
- Larder, B. A., Darby, G., & Richman, D. D.
- Affiliations
- Wellcome Trust (GB)
- University of California San Diego (US)
- ORCID
- Richman, Douglas D.
- Venue
- Science
- Published
- 1989-03-31
- Volume
- 243
- Issue
- 4899
- Pages
- 1731-1734
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086462809
- Cited by
- 1,559
- References
- 22
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 10 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 10 · 2014: 21 · 2013: 13 · 2012: 16
- FWCI
- 157.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HB-6-7019)
- National Institute of Allergy and Infectious Diseases (AI-62548, AI-52578)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV drug resistance, zidovudine resistance, AIDS, AIDS-related complex, antiretroviral therapy, 2',3'-dideoxycytidine, phosphonoformate
- MeSH terms
- Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Drug Resistance, HeLa Cells, HIV, Humans, Microbial Sensitivity Tests, Phosphonoacetic Acid, Viral Plaque Assay, Retroviridae Proteins, Virus Replication, Zidovudine, Dideoxynucleosides, Zalcitabine, HIV Core Protein p24, Foscarnet, Reverse Transcriptase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.